Fundraising Fox
Revalia Bio, Inc.
New Haven, US · Founded 2021 · Delaware corporation · 37 employees on LinkedIn · 7 known investors
Find your way into Revalia Bio, Inc.
Sign up to see every warm intro you have to Revalia Bio, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Revalia Bio, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Revalia Bio uses AI to convert donated human organs and tissues into multi-modal biological datasets and decision-ready insights for drug and device development. It operates an Organ ICU facility and works with organ procurement organizations and healthcare institutions to serve pharma, biotech, and medical device companies.
Founders & leadership
Revalia Bio, Inc. was founded in 2021 by Greg Tietjen, Jenna DiRito, Kourosh Saeb-Parsy, Helen Hughes, and Peter Buniak.
JD
Jenna DiRitoCo-FounderCo-founder of Revalia Bio, which uses AI to generate biological datasets and research insights from donated human organs and tissues for drug and device development.
KS
Kourosh Saeb-ParsyCo-FounderKourosh Saeb-Parsy is a transplant surgeon and medical director who has held board-level roles at life sciences organizations and worked with multinational biotech companies on clinical and translational research initiatives.
HH
Helen HughesCo-Founder & Chief People Officer
PB
Peter BuniakCo-Founder & AdvisorPeter Buniak previously served as Senior Vice President and Chief Information Officer at Kadmon Pharmaceuticals, where he led digital transformation across R&D, clinical, regulatory, and commercial functions before the company's acquisition by Sanofi. He is co-founder and advisor at Revalia Bio, a life sciences data platform company that operates an Organ ICU facility and applies machine learning to human organ datasets for pharmaceutical and biotech research.
JN
Janeta NikolovskiChief Data and Innovation Officer
QL
Quentin LashleyVP of IT & CybersecurityQuentin Lashley is VP of IT & Cybersecurity at Revalia Bio, an AI-driven platform that converts donated organs and tissues into biological datasets and insights for pharmaceutical and medical device development.
NB
Nabil BoutagyVP of Human Data Trial OperationsVP of Human Data Trial Operations at Revalia Bio. Over 15 years of research experience spanning benchtop, preclinical, and human research with expertise in vascular biology, cardiovascular imaging, and human metabolism; author of more than 50 peer-reviewed publications.
AS
Aniruth SarathyVP of EngineeringAniruth Sarathy is VP of Engineering at Revalia Bio and has previously scaled development teams and launched user-facing applications. He brings experience in product development, platform architecture, and deploying AI systems in enterprise environments.
Board
MA
BW
Investors · 7
BoxOne Ventureslisted by BoxOne VenturesMontréal · $500K
How we know: BoxOne Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Connecticut Innovationslisted by Connecticut InnovationsNew Haven · $500K – $2M
How we know: Connecticut Innovations's portfolio page · Not right? Tell us
Pamir Ventureslisted by Pamir VenturesSan Francisco
How we know: Pamir Ventures's portfolio page · Not right? Tell us
Sierra Ventureslisted by Sierra VenturesSan Mateo · $500K – $10M
How we know: Sierra Ventures's portfolio page · Not right? Tell us
Entrepreneur FirstreportedBengaluru · $1M – $7Mvia Milad Alucozai · board
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$12.3M disclosed across 1 round · 2024
▶$12.3MraisedNov 2024 · 32 investors · BiotechnologyRule 506(b)
▶$12.3MraisedNov 2024 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Milad AlucozaiDirector
- Brian WilcoveDirector
- Gregory T. TietjenExecutive Officer, Director
- Offering amount
- $17M
- Amount sold
- $12.3M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Life BiosciencesLife Biosciences is a biopharmaceutical company developing therapies focused on aging and age-related diseases, working across gene therapy and neuroscience programs. It advances drug candidates from discovery through clinical development.
Fortis Life SciencesFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Ancilia BioAncilia is a biotech company using CRISPR to create beneficial bacterial products, such as live biotherapeutics, that carry immunity against the viruses that destroy them. It develops computational and biological platforms to identify, characterize, and counter viruses within the microbiome (the virome).
VilyaVilya designs novel macrocycles using AI and computational biology to create medicines that don't exist in nature. The company develops therapeutics for disease by generating entirely new molecules with the targeting precision of antibodies but in pill form.
Companies working in the same space as Revalia Bio, Inc..
In the news
Frequently asked questions
- What does Revalia Bio, Inc. do?
- Revalia Bio uses AI to convert donated human organs and tissues into multi-modal biological datasets and decision-ready insights for drug and device development. It operates an Organ ICU facility and works with organ procurement organizations and healthcare institutions to serve pharma, biotech, and medical device companies.
- Who founded Revalia Bio, Inc.?
- Revalia Bio, Inc. was founded by Greg Tietjen, Jenna DiRito, Kourosh Saeb-Parsy, Helen Hughes, Peter Buniak in 2021.
- Who are Revalia Bio, Inc.'s investors?
- Revalia Bio, Inc.'s investors include America's Frontier Fund, BoxOne Ventures, Connecticut Innovations, Dnipro, Pamir Ventures, Sierra Ventures, Entrepreneur First.
- How much funding has Revalia Bio, Inc. raised?
- Revalia Bio, Inc. has disclosed $12.3M raised across 1 round.
- Where is Revalia Bio, Inc. headquartered?
- Revalia Bio, Inc. is headquartered in New Haven, US.